Sumitomo Pharma Co. Ltd
Sumitomo Pharma Co., Ltd. Manufactures, purchases, and sells pharmaceutical products for medical treatment in Japan, North America, and Asia. It offers therapeutic agents for parkinson's disease, type 2 diabetes, advanced prostate cancer, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. The company also provides atypical antipsychotic, generic products, an… Read more
Market Cap & Net Worth: Sumitomo Pharma Co. Ltd (SMDPY)
Sumitomo Pharma Co. Ltd (PINK:SMDPY) has a market capitalization of $1.90 Billion ($1.90 Billion) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #7855 globally and #4076 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sumitomo Pharma Co. Ltd's stock price $4.78 by its total outstanding shares 397289173 (397.29 Million).
Sumitomo Pharma Co. Ltd Market Cap History: 2022 to 2025
Sumitomo Pharma Co. Ltd's market capitalization history from 2022 to 2025. Data shows change from $3.05 Billion to $1.90 Billion (-17.04% CAGR).
Sumitomo Pharma Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sumitomo Pharma Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Sumitomo Pharma Co. Ltd's market cap is 0.00 times its annual revenue
1.02x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.08x
Sumitomo Pharma Co. Ltd's market cap is 0.08 times its annual earnings
10.35x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $3.05 Billion | $560.03 Billion | $56.41 Billion | 0.01x | 0.05x |
| 2023 | $1.28 Billion | $555.54 Billion | -$74.51 Billion | 0.00x | N/A |
| 2024 | $1.63 Billion | $314.56 Billion | -$314.97 Billion | 0.01x | N/A |
| 2025 | $1.90 Billion | $398.83 Billion | $23.63 Billion | 0.00x | 0.08x |
Competitor Companies of SMDPY by Market Capitalization
Companies near Sumitomo Pharma Co. Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to Sumitomo Pharma Co. Ltd by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Sumitomo Pharma Co. Ltd Historical Marketcap From 2022 to 2025
Between 2022 and today, Sumitomo Pharma Co. Ltd's market cap moved from $3.05 Billion to $ 1.90 Billion, with a yearly change of -17.04%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $1.90 Billion | +16.59% |
| 2024 | $1.63 Billion | +27.33% |
| 2023 | $1.28 Billion | -58.02% |
| 2022 | $3.05 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Sumitomo Pharma Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.90 Billion USD |
| MoneyControl | $1.90 Billion USD |
| MarketWatch | $1.90 Billion USD |
| marketcap.company | $1.90 Billion USD |
| Reuters | $1.90 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.